Authors: Jade Parker, Editor
Yet again the 60th American Society of Hematology (ASH) Annual Meeting and Exposition (December 1–4, 2018; CA, USA) has unearthed a wealth of hematologic research. Here, we compile the key headlines and ground-breaking research from the meeting. Highlights include:
- CASSINI data: DOACs could reduce blood clots for cancer patients
- Potentially practice-changing data for chronic lymphocytic leukemia
- MAIA: triplet regimen could replace standard of care for transplant-ineligible myeloma
CASSINI data: DOACs could reduce blood clots for cancer patients
One of the key late-breaking abstracts from the meeting was the CASSINI study. This trial demonstrated that taking Direct Oral Anticoagulants (DOACs) can reduce the risk of harmful blood clots in patients undergoing cancer treatments without substantially increasing the risk of bleeding problems.